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Cognitive impairment involves complex interactions between multiple
pathways and mechanisms, one of which being cardiac disorders. Atrial
cardiopathy (AC) is a structural and functional disorder of the left atrium
that may be a substrate for other cardiac disorders such as atrial fibrillation
(AF) and heart failure (HF). The association between AF and HF and cognitive
decline is clear; however, the relationship between AC and cognition requires
further investigation. Studies have shown that several markers of AC, such as
increased brain natriuretic peptide and left atrial enlargement, are associated
with an increased risk for cognitive impairment. The pathophysiology of
cognitive decline in patients with AC is not yet well understood. Advancing
our understanding of the relationship between AC and cognition may point
to important treatable targets and inform future therapeutic advancements.
This review presents our current understanding of the diagnosis of AC, as well
as clinical characteristics and potential pathways involved in the association
between AC and cognitive impairment.
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Introduction
Atrial cardiopathy (AC) is a recently described structural and functional disorder
of the left atrium (LA). The lack of a standardized definition for this condition reflects
the heterogeneous nature in the spectrum of disorders affecting the LA, resulting in an
increased risk of thromboembolic events. Potential biomarkers of AC include imaging,
electrophysiological, and serum abnormalities. AC may also be a substrate for multiple
primary cardiac disorders, including atrial fibrillation (AF) and heart failure (HF), and
has been linked to increased risk for stroke and higher stroke mortality (Ahmad et al.,
2020; Edwards et al., 2020). While the link between AF and HF and cognition is clear,
data on AC and cognition are scarce (Aldrugh et al., 2017; Rosler and Schnabel, 2020).
This review summarizes the relevant anatomical and functional pathways involved in
AC and the epidemiology, diagnosis, clinical characteristics, prognosis, and potential
treatments for AC and cognitive impairment. An overview of the proposed relationship
between AC and cognitive impairment is shown (Figure 1).
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Diagnostic criteria

Left atrial enlargement

A range of diagnostic criteria for AC has been proposed,
including the use of echocardiography, electrocardiography,
cardiac magnetic resonance imaging (MRI), and blood serum
markers (Yaghi et al., 2017). An overview of these diagnostic
criteria is provided (Table 1).
Echocardiography can be used to evaluate LA diameter or
volume, with LA enlargement being considered a marker of AC
(Goldberger et al., 2015). The most reliable measure is the LA
volume index, although it is more rarely reported (Healey et al.,
2019; Kamel et al., 2019). LA enlargement is also associated with
a higher rate of cardiovascular events and cardiovascular death
(Menichelli et al., 2020). Other echocardiography markers of AC
include spontaneous echocardiographic contrast and reduced
LA appendage flow velocity (Yaghi et al., 2017). Both of which
are also associated with an increased risk of thrombus formation
(Leung et al., 1994; Lee et al., 2014).
Multiple electrocardiogram measures may be used as
markers of AC, such as PR interval and P-wave terminal force
in V1 (Cheng et al., 2009; Yaghi et al., 2017). A prolonged
PR interval indicates first-degree atrioventricular block, a risk
factor for AF (Cheng et al., 2009). P-wave terminal force
measures electrical conduction and atrial dysfunction can cause
this to elevate (Yaghi et al., 2017). Further, disorders detected
using electrocardiogram, such as paroxysmal supraventricular
tachycardia and Bayes syndrome, may also indicate AC
(Yaghi et al., 2017).
LA fibrosis, which can be detected through cardiac MRI as
delayed uptake of gadolinium, is also used as a marker of AC
(Siebermair et al., 2017). LA fibrosis is characterized by collagen
deposits and disorganized myocytes, resulting in LA dysfunction
and arrhythmias such as AF (Nattel, 2017).
Lastly, brain natriuretic peptide (BNP) and cardiac troponin
are blood serum biomarkers of cardiac disease that can be used
to detect AC (Yaghi et al., 2017). Chronic elevation of troponin
and BNP have been associated with worse outcomes such as
stroke or death (Hijazi et al., 2014).

LA size is a known risk factor for cardiovascular events,
including AF, stroke, and HF, and may be present in both
systolic and diastolic heart dysfunction (Khoo et al., 2011;
Menichelli et al., 2020). It can be easily measured through
non-invasive tests such as transthoracic echocardiography
and is considered an important cardiovascular risk factor.
Evidence supporting the direct role for LA enlargement as
a cause of cognitive impairment is scarce. A prospective
study involving older adults from outpatient cardiology clinics
found that LA diameter was independently associated with
decreased cognitive function, especially regarding language and
memory domains, but no changes in whole brain volume
(Alosco et al., 2013). A previous study reported a positive
correlation between LA size and white matter hyperintensities,
a surrogate marker of cognitive dysfunction in the elderly
(Oh et al., 2012).
LA size and function have also been linked to cognitive
impairment through diverse mechanisms in patients with
HF and AF. LA enlargement directly correlates with left
ventricular diastolic dysfunction and chronic LA pressure to
volume overload, common findings in HF (Zile et al., 2011).
In a study including community-based elderly individuals,
LA enlargement and the presence of AF were significantly
associated with decreased cognitive function in a cross-sectional
analysis; however, with a longitudinal follow-up time of 5 years,
only AF was associated with increased cognitive impairment
(Zhang et al., 2019).

Increased brain natriuretic peptide
The relationship between BNP levels (a known marker
of AC) and cognitive impairment/dementia has been well
evaluated. Broadly, BNP levels have been associated with
both cognitive function as well as future risk of dementia.
It remains unknown if increased BNP is a marker of
dementia risk or has a causative role. BNP may serve as an
indicator of cognitive function in individuals with pre-existing
cardiovascular disease. In a study including adults greater than
55 years of age with known heart disease, it was found that
higher BNP levels are associated with worse cognitive function
(Gunstad et al., 2006).
Apolipoprotein-E (APOE) polymorphisms, particularly
APOE e4, are significant risk factors for neurological disorders,
such as Alzheimer’s disease. There is evidence that APOE e4
may also be a risk factor for cardiovascular disease. Further,
APOE e4 carriers have significantly higher BNP levels than noncarriers in individuals with HF (Pasqualetti et al., 2017). In
Alzheimer’s disease patients, BNP levels are also higher in those
that carry an APOE e4 allele (Begic et al., 2019). Contrarily,
healthy individuals that carry at least one APOE e4 allele have

Evidence linking atrial cardiopathy
with dementia
Several markers of AC have been associated with
dementia risk, including LA enlargement, increased BNP,
and electrocardiographic markers, but the relationship is
still unclear. AC and cognitive impairment share important
risk factors such as age, hypertension, heart failure, diabetes,
and obesity. Therefore, confounding variables may account
for the increased risk of dementia in patients with AC, and
further studies are required to investigate this association.
The current evidence linking markers of AC and dementia is
presented below.
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FIGURE 1

Overview of proposed relationship between atrial cardiopathy and cognitive impairment. Atrial cardiopathy, atrial fibrillation and heart failure all
share multiple risk factors and patho-mechanisms with cognitive impairment. The effects of atrial cardiopathy potentially predispose individuals
to cognitive impairment. Pathways that lead from atrial cardiopathy to cognitive impairment may include cerebral thromboembolism,
hypoperfusion, microbleeds, and brain volume loss. Created with Biorender.com.

TABLE 1 Proposed diagnostic criteria for AC.

Diagnostic method

Metrics

AC criteria

Echocardiography

LA volume or volume index; LA diameter or diameter index; LA area or area index

↑ LA size ↓ LA flow velocity

Electrocardiography

PR Interval P-wave terminal force in V1

↑ PR interval ↑ P-wave terminal force in V1

Cardiac MRI

Uptake of gadolinium

↑ LA fibrosis (decreased uptake of gadolinium)

Blood serum biomarkers

BNP Levels Cardiac troponin levels

↑ BNP ↑ Cardiac troponin

significantly lower BNP levels than non-carriers (Begic et al.,
2019). This suggests that comorbidities may alter the interplay
between APOE e4 status and BNP levels.
The implications for the relationship between BNP levels
and cognitive status are not limited to individuals with preexisting cardiovascular comorbidities. In a population-based
study of participants without dementia or cardiovascular
disease, higher BNP levels were associated with subclinical brain
damage, such as smaller total brain volume (Zonneveld et al.,
2017). Also in the general population, within a normal BNP
range, higher levels of BNP have been associated with mild
cognitive impairment (Kara et al., 2017).
Age is also an important factor when considering the
relationship between BNP and cognitive function. In general,
BNP levels increase with age, even in individuals without any
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cardiovascular disease (Redfield et al., 2002). BNP levels have
been associated with structural brain changes in both younger
and older (>60 years of age) individuals, but the structural
changes are accompanied by cognitive deficits only in the older
population (Veugen et al., 2018).
Beyond the association between BNP and current cognitive
status, it is also a risk factor for future cognitive decline.
Multiple longitudinal studies, with follow-up times from 10
to 14 years, found that BNP is an independent risk factor
for dementia/cognitive decline (Tynkkynen et al., 2015; Mirza
et al., 2016; Nagata et al., 2019; McGrath et al., 2020).
Further, when looking specifically at an elderly population
greater than 75 years of age, with a 5-year follow-up,
BNP was again a predictor of worsening cognitive function
(Kerola et al., 2010).
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Pathophysiology of atrial
cardiopathy-related cognitive
impairment

BNP is an established marker of AC; however, it is also a
marker of HF and AF, both of which are known risk factors for
dementia (Santangeli et al., 2012; Chen et al., 2018; Bailey et al.,
2021). Importantly, cognitive function may be further impaired
in individuals diagnosed with both HF and AF (Myserlis et al.,
2017). The commonality of BNP as a marker of AC, HF and AF,
raises the question of whether AC is just a bystander, or is it the
shared pathophysiological link between AF, HF, and dementia.
There is strong evidence for the association between BNP and
cognitive impairment, but further studies are required to tease
apart the role of AC in this relationship and to better understand
the pathophysiologic mechanisms.

Observational studies suggest that AC itself (in the absence
of HF or AF) is a risk factor for stroke and cognitive impairment
(Kamel et al., 2016; Freedman et al., 2020). However,
as mentioned in previous sections, the pathophysiology of
cognitive dysfunction in patients with AC is unknown and
research in this field is highly needed. The most likely
mechanism is increased LA thrombogenicity leading to cerebral
micro and macroembolism, similar to what has been described
in AF (Moretti and Caruso, 2020; Moroni et al., 2020).
Additionally, the pathophysiological association between AC
and cognitive impairment can be explained by the coexistence
of AF and HF. The role of these comorbidities as causes of
dementia and cognitive impairment in patients with AC are
discussed below.

Electrocardiographic abnormalities
In the last decade, several studies have found abnormal
P-wave indices (PWIs) to be independent risk factors for
cardioembolic ischemic stroke (Kamel et al., 2015; Maheshwari
et al., 2017; Chen and Soliman, 2019). PWIs include several
electrocardiographic measures such as P-wave axis, P-wave
duration, advanced interatrial block, P-wave area, P-wave
dispersion, and P-wave terminal force in V1. Most PWIs require
automated software, except for the P-wave axis which is the most
reported PWI. Electrocardiographic changes are common in the
elderly population, probably reflecting functional and structural
changes of the aging heart (Chiao and Rabinovitch, 2015). In
a study of 80 centenarians (mean age 101.4 ± 1.5 years), less
than 30% had a normal P wave, and almost half of them had an
interatrial block (Martinez-Selles et al., 2016).
Although less studied, there may be a relationship between
PWIs and cognitive impairment. Data from the communitybased cohort Atherosclerosis Risk in Communities (ARIC)
Neurocognitive Study with 25-year follow-up and 13,714
participants showed that abnormal PWIs are associated with
increased risk of cognitive impairment, independently of the
presence of AF and ischemic stroke (Gutierrez et al., 2019).
The underlying mechanisms between PWIs and cognitive
dysfunction are unknown but may involve subclinical cerebral
infarcts and decreased brain perfusion resulting in chronic
subcortical ischemia.
Interatrial block on electrocardiogram may also be a
valuable marker for different clinical outcomes, including stroke
and dementia. Its presence may predict AF, stroke, cognitive
impairment, and underlying AC based on atrial remodeling
(Bayes de Luna et al., 2017).
The prospective BAYES registry included elderly patients
with structural heart disease and absence of AF who were
followed for a median of 22 months. Results suggest interatrial
block (including both partial and advanced interatrial block)
may be a risk factor for cognitive impairment (Martinez-Selles
et al., 2020). This finding was also true for patients with mild
cognitive impairment (Herrera et al., 2020).
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Atrial fibrillation
Aging leads to changes in cardiac tissue structure and
function (including the LA and LA appendage) and is a
leading risk factor for cardiovascular disease (Chiao and
Rabinovitch, 2015). Although the exact molecular mechanisms
and the clinical consequences of atrial aging are unknown,
epicardial fat seems to be an essential source of cytokines
stimulating myocardial remodeling through connective tissue
proliferation (Pandit et al., 2016). Atrial fibrotic remodeling is
a distinctive feature of AC, promoting electrical and autonomic
remodeling, thus facilitating the development of both AF
and cardioembolism (Jalini et al., 2019; Shen et al., 2019).
Chronic inflammatory markers, including CRP, TNF-a, IL-2,
IL-6, and IL-8, are increased in patients with AF and may
provide an inflammatory background similar to what is seen in
other age-related conditions, providing a common mechanistic
pathway between AC, stroke, and cognitive impairment
(Aviles et al., 2003; Guo et al., 2012; Diener et al., 2019;
Forloni, 2020).
AF is a known risk factor for stroke, increasing the risk
by a factor of 4–5 (Wolf et al., 1991). While there is a clear
relationship between AF and cognitive decline, the literature
is inconclusive on whether risk of cognitive impairment is
independent of stroke risk in individuals with AF. A metaanalysis reported that AF is associated with cognitive decline
in patients with and without stroke (Kalantarian et al., 2013).
However, other studies have reported that the AF-related risk of
dementia can be explained by brain infarcts, with the majority
of infarcts being silent (Sposato et al., 2017; Kühne et al., 2022).
AF and dementia share multiple risk factors, and while many
studies adjust for these risk factors at baseline, they have short
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tomography, without a similar association in individuals with
AF (Johansen et al., 2020).

follow-up times and are not always reassessed (Rivard et al.,
2022). Further, subclinical AF could be a confounding cause of
dementia in patients with AC. Additional investigations, with
longer follow-up times and larger cohorts, are still required to
determine if there is a causal link between AF and dementia.
Our understanding of the shared patho-mechanisms
between AC and cognitive impairment is still developing, but
they are likely similar to those that have been implicated in AF.
Mechanisms involved in AF, such as inflammation, oxidative
stress, and senescence have been extensively reviewed elsewhere
(Guo et al., 2021; Sagris et al., 2021; Ihara and Sasano, 2022).

Conclusion
Cognitive impairment is a multifactorial disease state
with complex interactions between various mechanistic
pathways, including neurodegenerative and vascular injury.
However, clinical and subclinical cardiac disease may be
an important piece of this puzzle and a treatable target for
therapeutic intervention. AC may be a substrate for multiple
cardiac disorders, such as AF and HF. The association
between cognition and both AF and HF is well evaluated
but the literature examining AC and cognition is scarce. As
our knowledge of AC advances, we will develop a better
understanding of AC as a predictor or indicator of cognitive
decline. The relationship between AC and dementia may help
inform future diagnostic and therapeutic advancements
and warrants further investigation. Since there are no
proven disease-modifying therapies for dementia, large-scale,
multicenter collaborative efforts to evaluate preventive strategies
including oral anticoagulants, risk factors modifications, and
anti-inflammatory agents are needed.

Heart failure
HF is associated with a 27% increased risk of dementia
(Wolters et al., 2018). Low cardiac output in patients with
HF can result in reduced cerebral blood flow leading to
hypoperfusion of brain structures critical for cognitive function
(Adelborg et al., 2017). Impaired vascular autoregulation
resulting in white matter injury, neurohormonal dysregulation,
systemic inflammation, and cerebral microvascular dysfunction
may also contribute to generating a state of chronic cerebral
hypoxia leading to brain microinfarcts and neurodegeneration
(Adelborg et al., 2017). The latter may be enhanced by oxidative
stress, dendritic spine loss, glial activation, and programmed cell
death (Jinawong et al., 2021).
Local atrophy of structures involved in memory and other
cognitive domains (such as the parahippocampal gyrus) are
prominent in patients with HF without clinical dementia
(Meguro et al., 2017). This may constitute a treatable and
potentially preventable risk factor for cognitive impairment. In
a community-based sample of older adults, different left venticle
function markers (including echocardiographic parameters
and BNP levels) were also associated with structural and
functional changes in the brain and not entirely explained by
associated risk factors.
Evidence from the ARIC-PET (Atherosclerosis Risk in
Communities-positron emission tomography) Study revealed
a significant association between florbetapir (a high-affinity
beta-amyloid radiotracer) uptake and left ventricular structure
and using positron emission tomography (Johansen et al.,
2019). Whether these structural and functional changes in heart
tissue precede or occur concurrently with amyloid deposition
remains unknown.
Atrial dysfunction manifested as HF with preserved ejection
fraction may also be linked to cognitive dysfunction. Subclinical
ischemic stroke was common in patients with HF with
preserved ejection fraction and no prior AF diagnosis and
is associated with measurable cognitive deficits in the ARIC
cohort (Cogswell et al., 2017). One possible explanation may be
undiagnosed paroxysmal AF or AC. AC has also been linked
to increased brain amyloid deposition using positron emission
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